State of New Jersey Common Pension Fund D Trims Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

State of New Jersey Common Pension Fund D trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 198,702 shares of the biopharmaceutical company’s stock after selling 3,628 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.07% of Amicus Therapeutics worth $1,971,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of FOLD. Wellington Management Group LLP grew its position in Amicus Therapeutics by 101.9% during the 4th quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after purchasing an additional 7,666,335 shares during the last quarter. Norges Bank purchased a new stake in Amicus Therapeutics during the 4th quarter valued at about $35,915,000. Blackstone Inc. purchased a new stake in Amicus Therapeutics during the 4th quarter valued at about $35,008,000. Janus Henderson Group PLC grew its position in Amicus Therapeutics by 20.1% during the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after purchasing an additional 2,307,385 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Amicus Therapeutics by 583.4% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock valued at $25,640,000 after purchasing an additional 1,858,100 shares during the last quarter.

Amicus Therapeutics Stock Performance

FOLD opened at $11.29 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company has a market cap of $3.34 billion, a price-to-earnings ratio of -23.04 and a beta of 0.69. The company’s 50 day moving average is $11.04 and its 200 day moving average is $10.71. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm’s revenue was up 34.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.15) earnings per share. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,100 shares of company stock valued at $226,375. 2.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on FOLD. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research report on Friday. JPMorgan Chase & Co. dropped their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 16th. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.